Acumen Price To Sales Ratio vs Book Value Per Share Analysis

ABOS Stock

USD 1.73 0.04 2.26%

Acumen Pharmaceuticals financial indicator trend analysis is way more than just evaluating Acumen Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Acumen Pharmaceuticals is a good investment. Please check the relationship between Acumen Pharmaceuticals Price To Sales Ratio and its Book Value Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.

Price To Sales Ratio vs Book Value Per Share

Price To Sales Ratio vs Book Value Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Acumen Pharmaceuticals Price To Sales Ratio account and Book Value Per Share. At this time, the significance of the direction appears to have strong relationship.

The correlation between Acumen Pharmaceuticals' Price To Sales Ratio and Book Value Per Share is 0.61. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of Acumen Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Acumen Pharmaceuticals' Price To Sales Ratio and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Acumen Pharmaceuticals are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Price To Sales Ratio i.e., Acumen Pharmaceuticals' Price To Sales Ratio and Book Value Per Share go up and down completely randomly.

Correlation Coefficient

0.61

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Acumen Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Acumen Pharmaceuticals sales, a figure that is much harder to manipulate than other Acumen Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most indicators from Acumen Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Acumen Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.Selling General Administrative is likely to drop to about 11.3 M in 2025. Issuance Of Capital Stock is likely to drop to about 7.5 M in 2025

	2022	2023	2024	2025 (projected)
Interest Income	2.4M	8.2M	14.3M	15.0M
Net Interest Income	2.4M	8.2M	10.2M	10.8M

Interest Income Net Interest Income

Acumen Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.72	0.73	0.99	0.95	-0.56	-0.88	0.66	0.76	0.94	0.41	-0.9	1.0	0.61	0.9	-0.01	0.26	0.87	0.98	0.32	0.99	1.0	0.99	0.77	-0.42	-0.83
Other Current Liab	0.72		1.0	0.68	0.78	-0.03	-0.94	0.98	0.29	0.78	0.54	-0.76	0.69	0.96	0.87	0.24	0.71	0.79	0.76	0.62	0.67	0.69	0.66	0.81	-0.89	-0.71
Total Current Liabilities	0.73	1.0		0.69	0.79	-0.04	-0.95	0.98	0.29	0.79	0.56	-0.76	0.7	0.96	0.88	0.22	0.7	0.8	0.77	0.6	0.69	0.7	0.67	0.81	-0.89	-0.72
Total Stockholder Equity	0.99	0.68	0.69		0.96	-0.64	-0.85	0.62	0.82	0.9	0.32	-0.91	1.0	0.54	0.85	-0.04	0.19	0.85	0.97	0.27	0.99	1.0	1.0	0.7	-0.39	-0.81
Net Tangible Assets	0.95	0.78	0.79	0.96		-0.56	-0.92	0.77	0.76	0.87	0.36	-0.87	0.96	0.63	0.89	-0.18	0.2	0.91	0.96	0.2	0.96	0.96	0.95	0.68	-0.58	-0.79
Net Debt	-0.56	-0.03	-0.04	-0.64	-0.56		0.25	-0.03	-0.96	-0.27	0.37	0.61	-0.62	0.21	-0.25	0.31	0.54	-0.42	-0.5	0.24	-0.57	-0.62	-0.65	0.08	-0.18	0.38
Retained Earnings	-0.88	-0.94	-0.95	-0.85	-0.92	0.25		-0.93	-0.5	-0.9	-0.59	0.83	-0.86	-0.86	-0.96	-0.04	-0.52	-0.89	-0.92	-0.45	-0.87	-0.86	-0.84	-0.84	0.76	0.84
Accounts Payable	0.66	0.98	0.98	0.62	0.77	-0.03	-0.93		0.26	0.71	0.53	-0.69	0.63	0.92	0.85	0.1	0.62	0.8	0.73	0.5	0.63	0.64	0.6	0.73	-0.92	-0.66
Cash	0.76	0.29	0.29	0.82	0.76	-0.96	-0.5	0.26		0.52	-0.15	-0.78	0.81	0.06	0.5	-0.23	-0.31	0.61	0.72	-0.07	0.77	0.81	0.83	0.19	-0.03	-0.58
Non Current Assets Total	0.94	0.78	0.79	0.9	0.87	-0.27	-0.9	0.71	0.52		0.61	-0.78	0.9	0.74	0.95	0.11	0.47	0.88	0.95	0.47	0.93	0.91	0.89	0.92	-0.47	-0.76
Non Currrent Assets Other	0.41	0.54	0.56	0.32	0.36	0.37	-0.59	0.53	-0.15	0.61		-0.17	0.35	0.63	0.66	0.01	0.56	0.41	0.51	0.32	0.42	0.35	0.32	0.8	-0.41	-0.62
Other Assets	-0.9	-0.76	-0.76	-0.91	-0.87	0.61	0.83	-0.69	-0.78	-0.78	-0.17		-0.91	-0.62	-0.8	-0.24	-0.33	-0.79	-0.87	-0.51	-0.86	-0.91	-0.9	-0.63	0.48	0.76
Cash And Short Term Investments	1.0	0.69	0.7	1.0	0.96	-0.62	-0.86	0.63	0.81	0.9	0.35	-0.91		0.56	0.86	-0.04	0.2	0.85	0.97	0.28	0.99	1.0	1.0	0.71	-0.39	-0.83
Net Receivables	0.61	0.96	0.96	0.54	0.63	0.21	-0.86	0.92	0.06	0.74	0.63	-0.62	0.56		0.81	0.38	0.86	0.67	0.65	0.72	0.56	0.56	0.53	0.86	-0.87	-0.62
Common Stock Shares Outstanding	0.9	0.87	0.88	0.85	0.89	-0.25	-0.96	0.85	0.5	0.95	0.66	-0.8	0.86	0.81		0.08	0.49	0.93	0.95	0.49	0.88	0.87	0.84	0.89	-0.6	-0.8
Non Current Liabilities Total	-0.01	0.24	0.22	-0.04	-0.18	0.31	-0.04	0.1	-0.23	0.11	0.01	-0.24	-0.04	0.38	0.08		0.7	-0.07	-0.06	0.9	-0.11	-0.04	-0.07	0.31	-0.08	0.03
Inventory	0.26	0.71	0.7	0.19	0.2	0.54	-0.52	0.62	-0.31	0.47	0.56	-0.33	0.2	0.86	0.49	0.7		0.26	0.28	0.86	0.19	0.2	0.17	0.73	-0.65	-0.34
Other Current Assets	0.87	0.79	0.8	0.85	0.91	-0.42	-0.89	0.8	0.61	0.88	0.41	-0.79	0.85	0.67	0.93	-0.07	0.26		0.92	0.32	0.87	0.85	0.83	0.71	-0.54	-0.62
Other Stockholder Equity	0.98	0.76	0.77	0.97	0.96	-0.5	-0.92	0.73	0.72	0.95	0.51	-0.87	0.97	0.65	0.95	-0.06	0.28	0.92		0.32	0.98	0.97	0.96	0.8	-0.47	-0.84
Total Liab	0.32	0.62	0.6	0.27	0.2	0.24	-0.45	0.5	-0.07	0.47	0.32	-0.51	0.28	0.72	0.49	0.9	0.86	0.32	0.32		0.22	0.28	0.24	0.64	-0.4	-0.3
Net Invested Capital	0.99	0.67	0.69	0.99	0.96	-0.57	-0.87	0.63	0.77	0.93	0.42	-0.86	0.99	0.56	0.88	-0.11	0.19	0.87	0.98	0.22		0.99	0.99	0.74	-0.39	-0.82
Total Current Assets	1.0	0.69	0.7	1.0	0.96	-0.62	-0.86	0.64	0.81	0.91	0.35	-0.91	1.0	0.56	0.87	-0.04	0.2	0.85	0.97	0.28	0.99		1.0	0.72	-0.4	-0.83
Net Working Capital	0.99	0.66	0.67	1.0	0.95	-0.65	-0.84	0.6	0.83	0.89	0.32	-0.9	1.0	0.53	0.84	-0.07	0.17	0.83	0.96	0.24	0.99	1.0		0.69	-0.37	-0.82
Short Long Term Debt Total	0.77	0.81	0.81	0.7	0.68	0.08	-0.84	0.73	0.19	0.92	0.8	-0.63	0.71	0.86	0.89	0.31	0.73	0.71	0.8	0.64	0.74	0.72	0.69		-0.55	-0.72
Common Stock Total Equity	-0.42	-0.89	-0.89	-0.39	-0.58	-0.18	0.76	-0.92	-0.03	-0.47	-0.41	0.48	-0.39	-0.87	-0.6	-0.08	-0.65	-0.54	-0.47	-0.4	-0.39	-0.4	-0.37	-0.55		0.48
Retained Earnings Total Equity	-0.83	-0.71	-0.72	-0.81	-0.79	0.38	0.84	-0.66	-0.58	-0.76	-0.62	0.76	-0.83	-0.62	-0.8	0.03	-0.34	-0.62	-0.84	-0.3	-0.82	-0.83	-0.82	-0.72	0.48

Click cells to compare fundamentals

Acumen Pharmaceuticals Account Relationship Matchups

Acumen Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	44.4M	230.3M	196.6M	310.1M	239.0M	188.4M
Other Current Liab	5.8M	4.1M	6.0M	9.9M	21.7M	22.8M
Total Current Liabilities	6.4M	5.1M	7.8M	13.0M	27.6M	29.0M
Total Stockholder Equity	38.1M	225.2M	188.8M	267.0M	181.8M	163.1M
Net Debt	(43.8M)	(122.2M)	(130.0M)	(38.4M)	(5.9M)	(6.2M)
Retained Earnings	(27.0M)	(127.6M)	(170.4M)	(222.8M)	(325.1M)	(308.9M)
Accounts Payable	531K	1.1M	1.6M	1.4M	5.6M	5.9M
Cash	43.8M	122.2M	130.1M	66.9M	35.6M	33.8M
Non Current Assets Total	0.0	31.7M	16.3M	63.5M	60.7M	31.6M
Cash And Short Term Investments	43.8M	194.2M	177.6M	243.5M	171.6M	153.5M
Net Receivables	109K	(83.0)	(199.0)	225K	398K	417.9K
Liabilities And Stockholders Equity	44.4M	230.3M	196.6M	310.1M	239.0M	188.4M
Non Current Liabilities Total	56.7M	4.1M	1.7M	30.2M	29.6M	18.6M
Inventory	91K	83.0	199.0	98K	112.7K	118.3K
Other Current Assets	543K	4.4M	2.7M	2.9M	6.4M	3.2M
Other Stockholder Equity	8.4M	353.0M	359.9M	489.5M	507.0M	316.4M
Total Liab	63.0M	5.1M	7.8M	43.2M	57.2M	35.8M
Net Invested Capital	(18.6M)	225.2M	188.8M	294.3M	210.3M	162.9M
Total Current Assets	44.4M	198.7M	180.3M	246.6M	178.3M	156.8M
Net Working Capital	38.1M	193.5M	172.5M	233.6M	150.7M	145.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Acumen Stock Analysis

When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC